Checkpoint Therapeutics Stock
Checkpoint Therapeutics Stock
The community is currently still undecided about Checkpoint Therapeutics with 2 Buy predictions and 0 Sell predictions.
With a target price of 4 € there is potential for a 698.08% increase which would mean more than doubling the current price of 0.5 € for Checkpoint Therapeutics.
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Ardelyx Inc. | -0.760% | -1.247% | 32.166% | 23.657% | 32.166% | 152.804% | 2.624% |
| Evolus Inc | -2.050% | -7.282% | -29.908% | -71.704% | -29.908% | -57.318% | -27.487% |
| Champions Oncology Inc | -1.600% | 7.895% | 6.034% | -41.429% | 6.034% | 66.216% | -32.044% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat